The share

[{"d":"2025-01-17","n":"Buvidal® weekly and monthly – now available to patients in Switzerland","u":"/media/press-releases/2025/buvidal-weekly-and-monthly-now-available-to-patients-in-switzerland/"},{"d":"2025-01-23","n":"Camurus’ fourth quarter and full year 2024 earnings above previous estimates","u":"/media/press-releases/2025/camurus-fourth-quarter-and-full-year-2024-earnings-above-previous-estimates/"},{"d":"2025-02-13","n":"Camurus’ Full Year Report 2024","u":"/media/press-releases/2025/camurus-full-year-report-2024/"},{"d":"2024-01-17","n":"Camurus intends to carry out a directed share issue of approximately 2 million shares and provides preliminary financial information for FY 2023","u":"/media/press-releases/2024/camurus-intends-to-carry-out-a-directed-share-issue-of-approximately-2-million-shares-and-provides-preliminary-financial-information-for-fy-2023/"},{"d":"2024-01-18","n":"Camurus has carried out a directed share issue of 2,000,000 shares at a subscription price of SEK 545 per share, raising gross proceeds of SEK 1,090 million","u":"/media/press-releases/2024/camurus-has-carried-out-a-directed-share-issue-of-2000000-shares-at-a-subscription-price-of-sek-545-per-share-raising-gross-proceeds-of-sek-1090-million/"},{"d":"2024-01-31","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2024/change-in-number-of-shares-and-votes-in-camurus/"},{"d":"2024-02-08","n":"Completed enrollment in the POSITANO study of CAM2029 in patients with polycystic liver disease","u":"/media/press-releases/2024/completed-enrollment-in-the-positano-study-of-cam2029-in-patients-with-polycystic-liver-disease/"},{"d":"2024-02-13","n":"Camurus appoints Behshad Sheldon as President of Camurus Inc.","u":"/media/press-releases/2024/camurus-appoints-behshad-sheldon-as-president-of-camurus-inc-/"},{"d":"2024-02-15","n":"Camurus’ Full Year Report 2023","u":"/media/press-releases/2024/camurus-full-year-report-2023/"},{"d":"2024-03-05","n":"Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly","u":"/media/press-releases/2024/camurus-announces-fda-acceptance-of-nda-submission-for-oclaiz-for-treatment-of-acromegaly/"},{"d":"2024-03-28","n":"Camurus Annual Report for 2023","u":"/media/press-releases/2024/camurus-annual-report-for-2023/"},{"d":"2024-04-02","n":"Notice of annual general meeting 2024 in Camurus (publ)","u":"/media/press-releases/2024/notice-of-annual-general-meeting-2024-in-camurus-publ/"},{"d":"2024-05-08","n":"Camurus’ Interim Report January-March 2024","u":"/media/press-releases/2024/camurus-interim-report-january-march-2024/"},{"d":"2024-05-08","n":"Resolutions at the annual general meeting 2024 in Camurus","u":"/media/press-releases/2024/resolutions-at-the-annual-general-meeting-2024-in-camurus/"},{"d":"2024-05-23","n":"Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly","u":"/media/press-releases/2024/camurus-receives-ema-acceptance-of-maa-filing-for-octreotide-sc-depot-cam2029-for-the-treatment-of-acromegaly/"},{"d":"2024-05-28","n":"Camurus to present at Jefferies 2024 Healthcare Conference New York","u":"/media/press-releases/2024/camurus-to-present-at-jefferies-2024-healthcare-conference-new-york/"},{"d":"2024-05-30","n":"Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2024/2027","u":"/media/press-releases/2024/camurus-board-of-directors-exercises-authorization-for-repurchase-of-shares-for-the-purpose-of-securing-the-companys-commitments-under-the-performance-share-plan-20242027/"},{"d":"2024-06-12","n":"Exercise of Camurus’ employee stock options program 2021/2024","u":"/media/press-releases/2024/exercise-of-camurus-employee-stock-options-program-20212024/"},{"d":"2024-06-24","n":"Camurus submits its first UN Global Compact Communication on Progress and renews the Nasdaq Transparency Partner certificate","u":"/media/press-releases/2024/camurus-submits-its-first-un-global-compact-communication-on-progress-and-renews-the-nasdaq-transparency-partner-certificate/"},{"d":"2024-06-25","n":"New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl","u":"/media/press-releases/2024/new-publication-shows-effectiveness-data-for-weekly-and-monthly-buprenorphine-injections-in-treating-opioid-dependence-in-individuals-using-fentanyl/"},{"d":"2024-06-28","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2024/change-in-number-of-shares-and-votes-in-camurus/"},{"d":"2024-07-15","n":"Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients","u":"/media/press-releases/2024/camurus-announces-positive-phase-3-results-from-the-acroinnova-2-study-of-octreotide-sc-depot-cam2029-in-acromegaly-patients/"},{"d":"2024-07-16","n":"Camurus’ Interim Report Second Quarter 2024","u":"/media/press-releases/2024/camurus-interim-report-second-quarter-2024/"},{"d":"2024-07-25","n":"Camurus recognized in Fortune’s Top 25 “Leading the charge: Spotlighting the 25 companies smashing the glass ceiling”","u":"/media/press-releases/2024/camurus-recognized-in-fortunes-top-25-leading-the-charge-spotlighting-the-25-companies-smashing-the-glass-ceiling/"},{"d":"2024-09-19","n":"Exercise in Camurus’ employee stock options program 2021/2024","u":"/media/press-releases/2024/exercise-in-camurus-employee-stock-options-program-20212024/"},{"d":"2024-09-20","n":"EMA positive opinion for orphan drug designation to Camurus’ octreotide SC depot for the treatment of polycystic liver disease","u":"/media/press-releases/2024/ema-positive-opinion-for-orphan-drug-designation-to-camurus-octreotide-sc-depot-for-the-treatment-of-polycystic-liver-disease/"},{"d":"2024-09-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2024/change-in-number-of-shares-and-votes-in-camurus/"},{"d":"2024-10-21","n":"Camurus provides regulatory update on the US NDA for CAM2029 in acromegaly","u":"/media/press-releases/2024/camurus-provides-regulatory-update-on-the-us-nda-for-cam2029-in-acromegaly/"},{"d":"2024-10-28","n":"Camurus improves ESG rating score by MSCI","u":"/media/press-releases/2024/camurus-improves-esg-rating-score-by-msci/"},{"d":"2024-11-07","n":"Camurus’ Interim Report Third Quarter 2024","u":"/media/press-releases/2024/camurus-interim-report-third-quarter-2024/"},{"d":"2024-11-11","n":"Camurus to present at Jefferies London Healthcare Conference","u":"/media/press-releases/2024/camurus-to-present-at-jefferies-london-healthcare-conference/"},{"d":"2024-11-12","n":"Camurus’ Nomination Committee appointed for the Annual General Meeting 2025","u":"/media/press-releases/2024/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2025/"},{"d":"2024-12-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2024/change-in-number-of-shares-and-votes-in-camurus-2024-12-30/"},{"d":"2023-02-13","n":"Camurus withdraws variation application for CAM2038 to include chronic pain","u":"/media/press-releases/2023/camurus-withdraws-variation-application-for-cam2038-to-include-chronic-pain/"},{"d":"2023-02-14","n":"Camurus’ Full Year Report 2022","u":"/media/press-releases/2023/camurus-full-year-report-2022/"},{"d":"2023-03-30","n":"Camurus Annual Report for 2022","u":"/media/press-releases/2023/camurus-annual-report-for-2022/"},{"d":"2023-04-04","n":"Notice of annual general meeting 2023 in Camurus AB (publ)","u":"/media/press-releases/2023/notice-of-annual-general-meeting-2023-in-camurus-ab-publ/"},{"d":"2023-04-04","n":"Camurus appoints Alberto Pedroncelli as Chief Medical Officer","u":"/media/press-releases/2023/camurus-appoints-alberto-pedroncelli-as-chief-medical-officer/"},{"d":"2023-05-10","n":"Camurus’ Interim Report January-March 2023","u":"/media/press-releases/2023/camurus-interim-report-january-march-2023/"},{"d":"2023-05-10","n":"Resolutions at the annual general meeting 2023 in Camurus","u":"/media/press-releases/2023/resolutions-at-the-annual-general-meeting-2023-in-camurus/"},{"d":"2023-05-23","n":"Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder","u":"/media/press-releases/2023/camurus-announces-fda-approval-of-brixadi-for-the-treatment-of-moderate-to-severe-opioid-use-disorder/"},{"d":"2023-05-29","n":"Camurus to present at Jefferies 2023 Healthcare Conference New York","u":"/media/press-releases/2023/camurus-to-present-at-jefferies-2023-healthcare-conference-new-york/"},{"d":"2023-05-31","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2023/change-in-number-of-shares-and-votes-in-camurus/"},{"d":"2023-06-19","n":"Camurus accepted as participant of the United Nations Global Compact","u":"/media/press-releases/2023/camurus-accepted-as-participant-of-the-united-nations-global-compact/"},{"d":"2023-06-20","n":"Camurus’ octreotide SC depot (CAM2029) achieves superior treatment response compared to placebo in Phase 3 acromegaly trial","u":"/media/press-releases/2023/camurus-octreotide-sc-depot-cam2029-achieves-superior-treatment-response-compared-to-placebo-in-phase-3-acromegaly-trial/"},{"d":"2023-07-17","n":"Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly","u":"/media/press-releases/2023/camurus-announces-new-phase-3-data-reinforcing-long-term-safety-and-efficacy-of-octreotide-sc-depot-cam2029-in-patients-with-acromegaly/"},{"d":"2023-07-18","n":"Camurus’ Interim Report Second Quarter 2023","u":"/media/press-releases/2023/camurus-interim-report-second-quarter-2023/"},{"d":"2023-08-25","n":"Exercise of Camurus’ subscription warrant program 2020/2023","u":"/media/press-releases/2023/exercise-of-camurus-subscription-warrant-program-20202023/"},{"d":"2023-08-31","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2023/change-in-number-of-shares-and-votes-in-camurus-2023-08-31/"},{"d":"2023-09-05","n":"Camurus announces US launch of Brixadi™ for the treatment of moderate to severe opioid use disorder by Braeburn","u":"/media/press-releases/2023/camurus-announces-us-launch-of-brixadi-for-the-treatment-of-moderate-to-severe-opioid-use-disorder-by-braeburn/"},{"d":"2023-09-26","n":"Camurus establishes new, sustainable headquarters and laboratories in Science Village, Lund","u":"/media/press-releases/2023/camurus-establishes-new-sustainable-headquarters-and-laboratories-in-science-village-lund/"},{"d":"2023-10-18","n":"Camurus’ Nomination Committee appointed for the Annual General Meeting 2024","u":"/media/press-releases/2023/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2024/"},{"d":"2023-10-23","n":"Camurus raises financial guidance for the full year 2023","u":"/media/press-releases/2023/camurus-raises-financial-guidance-for-the-full-year-2023/"},{"d":"2023-11-01","n":"Camurus to present at Jefferies 2023 Healthcare Conference London","u":"/media/press-releases/2023/camurus-to-present-at-jefferies-2023-healthcare-conference-london/"},{"d":"2023-11-06","n":"Camurus receives improved ESG risk rating by Sustainalytics","u":"/media/press-releases/2023/camurus-receives-improved-esg-risk-rating-by-sustainalytics/"},{"d":"2023-11-09","n":"Camurus’ Interim Report Third Quarter 2023","u":"/media/press-releases/2023/camurus-interim-report-third-quarter-2023/"},{"d":"2023-12-14","n":"Camurus announces completed enrollment in the Phase 3 SORENTO study of CAM2029 in patients with neuroendocrine tumors","u":"/media/press-releases/2023/camurus-announces-completed-enrollment-in-the-phase-3-sorento-study-of-cam2029-in-patients-with-neuroendocrine-tumors/"},{"d":"2023-12-20","n":"Camurus to enter Large Cap segment on Nasdaq Stockholm","u":"/media/press-releases/2023/camurus-to-enter-large-cap-segment-on-nasdaq-stockholm/"},{"d":"2023-12-21","n":"Camurus submits New Drug Application to the US FDA for Oclaiz™ for treatment of acromegaly","u":"/media/press-releases/2023/camurus-submits-new-drug-application-to-the-us-fda-for-oclaiz-for-treatment-of-acromegaly/"},{"d":"2023-12-29","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2023/change-in-number-of-shares-and-votes-in-camurus-2023-12-29/"},{"d":"2022-04-04","n":"2021 and 2020 Lipid Science Prize awarded to inventors of m-RNA and lipid nanoparticle technologies","u":"/media/press-releases/2022/2021-and-2020-lipid-science-prize-awarded-to-inventors-of-m-rna-and-lipid-nanoparticle-technologies/"},{"d":"2022-04-06","n":"Notice of annual general meeting 2022 in Camurus AB (publ)","u":"/media/press-releases/2022/notice-of-annual-general-meeting-2022-in-camurus-ab-publ/"},{"d":"2022-04-06","n":"Camurus Annual Report for 2021","u":"/media/press-releases/2022/camurus-annual-report-for-2021/"},{"d":"2022-05-12","n":"Resolutions at the annual general meeting 2022 in Camurus","u":"/media/press-releases/2022/resolutions-at-the-annual-general-meeting-2022-in-camurus/"},{"d":"2022-05-31","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2022/change-in-number-of-shares-and-votes-in-camurus/"},{"d":"2022-06-07","n":"Camurus to present at Jefferies 2022 Healthcare Conference New York","u":"/media/press-releases/2022/camurus-to-present-at-jefferies-2022-healthcare-conference-new-york/"},{"d":"2022-06-10","n":"Invitation to Camurus’ Capital Markets and R&D Day 6 September 2022","u":"/media/press-releases/2022/invitation-to-camurus-capital-markets-and-rd-day-6-september-2022/"},{"d":"2022-06-14","n":"Camurus appoints Jonas Duborn as Head of Compliance","u":"/media/press-releases/2022/camurus-appoints-jonas-duborn-as-head-of-compliance/"},{"d":"2022-06-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2022/change-in-number-of-shares-and-votes-in-camurus-2022-06-30/"},{"d":"2022-07-08","n":"Solasia acquires episil oral liquid business from Camurus","u":"/media/press-releases/2022/solasia-acquires-episil-oral-liquid-business-from-camurus/"},{"d":"2022-07-15","n":"Camurus’ Interim Report Second Quarter 2022","u":"/media/press-releases/2022/camurus-interim-report-second-quarter-2022/"},{"d":"2022-08-23","n":"Exercise of Camurus’ subscription warrant program 2019/2022","u":"/media/press-releases/2022/exercise-of-camurus-subscription-warrant-program-20192022/"},{"d":"2022-08-26","n":"Program for Camurus’ Capital Markets and R&D Day 6 September 2022","u":"/media/press-releases/2022/program-for-camurus-capital-markets-and-rd-day-6-september-2022/"},{"d":"2022-08-30","n":"Camurus supports International Overdose Awareness Day 2022","u":"/media/press-releases/2022/camurus-supports-international-overdose-awareness-day-2022/"},{"d":"2022-08-31","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2022/change-in-number-of-shares-and-votes-in-camurus-2022-08-31/"},{"d":"2022-08-31","n":"Update of change in number of shares and votes in Camurus","u":"/media/press-releases/2022/update-of-change-in-number-of-shares-and-votes-in-camurus/"},{"d":"2022-09-06","n":"Camurus presenting five-year vision for growth and financial outlook at Capital Markets and R&D Day","u":"/media/press-releases/2022/camurus-presenting-five-year-vision-for-growth-and-financial-outlook-at-capital-markets-and-rd-day/"},{"d":"2022-10-19","n":"Camurus’ Nomination Committee appointed for the Annual General Meeting 2023","u":"/media/press-releases/2022/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2023/"},{"d":"2022-10-28","n":"Camurus supports two Global Awareness Days for rare diseases","u":"/media/press-releases/2022/camurus-supports-two-global-awareness-days-for-rare-diseases/"},{"d":"2022-11-11","n":"Camurus to present at Jefferies 2022 Healthcare Conference London","u":"/media/press-releases/2022/camurus-to-present-at-jefferies-2022-healthcare-conference-london/"},{"d":"2022-11-23","n":"Camurus announces that Braeburn resubmits NDA for Brixadi™ in the US","u":"/media/press-releases/2022/camurus-announces-that-braeburn-resubmits-nda-for-brixadi-in-the-us/"},{"d":"2022-12-08","n":"Camurus announces PDUFA date for Brixadi™ NDA for the treatment of opioid use disorder in the US","u":"/media/press-releases/2022/camurus-announces-pdufa-date-for-brixadi-nda-for-the-treatment-of-opioid-use-disorder-in-the-us/"},{"d":"2022-12-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2022/change-in-number-of-shares-and-votes-in-camurus-2022-12-30/"},{"d":"2022-02-16","n":"Camurus’ Full Year Report 2021","u":"/media/press-releases/2022/camurus-full-year-report-2021/"},{"d":"2022-05-12","n":"Camurus' Interim Report January-March 2022","u":"/media/press-releases/2022/camurus-interim-report-january-march-2022/"},{"d":"2022-11-10","n":"Camurus’ Interim Report Third Quarter 2022","u":"/media/press-releases/2022/camurus-interim-report-third-quarter-2022/"},{"d":"2022-01-13","n":"Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder","u":"/media/press-releases/2022/camurus-announces-dosing-initiated-in-phase-3-trial-of-weekly-setmelanotide-in-patients-with-genetic-obesity-disorder/"},{"d":"2021-12-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus/"},{"d":"2021-12-15","n":"Braeburn receives new Complete Response Letter for Brixadi in the US","u":"/media/press-releases/2021/braeburn-receives-new-complete-response-letter-for-brixadi-in-the-us/"},{"d":"2021-11-30","n":"The European Medicines Agency accepts application to extend the Buvidal indication to include treatment of chronic pain","u":"/media/press-releases/2021/the-european-medicines-agency-accepts-application-to-extend-the-buvidal-indication-to-include-treatment-of-chronic-pain/"},{"d":"2021-11-11","n":"Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors","u":"/media/press-releases/2021/camurus-announces-dosing-initiated-in-phase-3-study-of-cam2029-in-patients-with-neuroendocrine-tumors/"},{"d":"2021-11-04","n":"Camurus’ Interim Report Third Quarter 2021","u":"/media/press-releases/2021/camurus-interim-report-third-quarter-2021/"},{"d":"2021-10-27","n":"Camurus’ Nomination Committee appointed for the Annual General Meeting 2022","u":"/media/press-releases/2021/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2022/"},{"d":"2021-10-13","n":"Camurus appoints Jon U. Garay Alonso as Chief Financial Officer","u":"/media/press-releases/2021/camurus-appoints-jon-u-garay-alonso-as-chief-financial-officer/"},{"d":"2021-09-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-09-30/"},{"d":"2021-09-16","n":"FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease","u":"/media/press-releases/2021/fda-grants-orphan-drug-designation-in-the-us-for-cam2029-for-the-treatment-of-polycystic-liver-disease/"},{"d":"2021-09-15","n":"Camurus’ Chief Financial Officer (CFO) will leave the company","u":"/media/press-releases/2021/camurus-chief-financial-officer-cfo-will-leave-the-company/"},{"d":"2021-08-31","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-08-31/"},{"d":"2021-07-15","n":"Camurus’ Interim Report Second Quarter 2021","u":"/media/press-releases/2021/camurus-interim-report-second-quarter-2021/"},{"d":"2021-06-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-06-30/"},{"d":"2021-06-26","n":"Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US","u":"/media/press-releases/2021/camurus-announces-pdufa-date-for-brixadi-for-the-treatment-of-opioid-use-disorder-in-the-us/"},{"d":"2021-06-15","n":"Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US","u":"/media/press-releases/2021/camurus-announces-braeburn-resubmits-new-drug-application-for-brixadi-in-the-us/"},{"d":"2021-05-31","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-05-31/"},{"d":"2021-05-21","n":"Exercise of Camurus’ subscription warrant program 2018/2021","u":"/media/press-releases/2021/exercise-of-camurus-subscription-warrant-program-20182021/"},{"d":"2021-05-19","n":"Camurus receives Carnegie Sustainability Award 2021","u":"/media/press-releases/2021/camurus-receives-carnegie-sustainability-award-2021/"},{"d":"2021-05-10","n":"Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence","u":"/media/press-releases/2021/camurus-announces-publication-showing-superior-patient-treatment-satisfaction-with-buvidal-weekly-and-monthly-depot-injections-in-opioid-dependence/"},{"d":"2021-05-06","n":"Resolutions at the annual general meeting 2021 in Camurus","u":"/media/press-releases/2021/resolutions-at-the-annual-general-meeting-2021-in-camurus/"},{"d":"2021-05-06","n":"Camurus’ Interim Report January-March 2021","u":"/media/press-releases/2021/camurus-interim-report-january-march-2021/"},{"d":"2021-05-03","n":"The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence","u":"/media/press-releases/2021/the-australian-tga-approves-key-label-updates-to-buvidal-for-treatment-of-opioid-dependence/"},{"d":"2021-04-14","n":"Camurus Annual Report for 2020","u":"/media/press-releases/2021/camurus-annual-report-for-2020/"},{"d":"2021-03-30","n":"Notice of annual general meeting 2021 in Camurus AB (publ)","u":"/media/press-releases/2021/notice-of-annual-general-meeting-2021-in-camurus-ab-publ/"},{"d":"2021-03-26","n":"Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence","u":"/media/press-releases/2021/camurus-receives-positive-chmp-opinion-for-buvidal-160mg-monthly-dose-for-the-treatment-of-opioid-dependence/"},{"d":"2021-02-11","n":"Camurus’ Full Year Report 2020","u":"/media/press-releases/2021/camurus-full-year-report-2020/"},{"d":"2021-01-29","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-01-29/"},{"d":"2021-01-04","n":"Camurus appoints Andrew McLean as Vice President Corporate Development and Senior Counsel","u":"/media/press-releases/2021/camurus-appoints-andrew-mclean-as-vice-president-corporate-development-and-senior-counsel/"},{"d":"2020-12-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2020/change-in-number-of-shares-and-votes-in-camurus/"},{"d":"2020-12-18","n":"Swissmedic approves Buvidal for the treatment of opioid dependence","u":"/media/press-releases/2020/swissmedic-approves-buvidal-for-the-treatment-of-opioid-dependence/"},{"d":"2020-12-18","n":"Exercise of Camurus’ subscription warrant program 2017/2020","u":"/media/press-releases/2020/exercise-of-camurus-subscription-warrant-program-20172020/"},{"d":"2020-12-10","n":"Camurus announces outcome of the arbitration process with Braeburn","u":"/media/press-releases/2020/camurus-announces-outcome-of-the-arbitration-process-with-braeburn/"},{"d":"2020-12-02","n":"Camurus announces that Braeburn receives Complete Response Letter for Brixadi for opioid use disorder in the US","u":"/media/press-releases/2020/camurus-announces-that-braeburn-receives-complete-response-letter-for-brixadi-for-opioid-use-disorder-in-the-us/"},{"d":"2020-11-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2020/change-in-number-of-shares-and-votes-in-camurus-2020-11-30/"},{"d":"2020-11-05","n":"Camurus’ Interim Report Third Quarter 2020","u":"/media/press-releases/2020/camurus-interim-report-third-quarter-2020/"},{"d":"2020-10-23","n":"Camurus’ Nomination Committee appointed for the Annual General Meeting 2021","u":"/media/press-releases/2020/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2021/"},{"d":"2020-07-31","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2020/change-in-number-of-shares-and-votes-in-camurus-2020-07-31/"},{"d":"2020-07-16","n":"Camurus’ Interim Report Second Quarter 2020","u":"/media/press-releases/2020/camurus-interim-report-second-quarter-2020/"},{"d":"2020-07-02","n":"Camurus has completed a directed share issue of 2 million shares, raising proceeds of SEK 300 million","u":"/media/press-releases/2020/camurus-has-completed-a-directed-share-issue-of-2-million-shares-raising-proceeds-of-sek-300-million/"},{"d":"2020-07-01","n":"Camurus intends to carry out a directed share issue of approximately SEK 300 million","u":"/media/press-releases/2020/camurus-intends-to-carry-out-a-directed-share-issue-of-approximately-sek-300-million/"},{"d":"2020-06-24","n":"Positive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers with obesity","u":"/media/press-releases/2020/positive-results-from-phase-2-study-of-once-weekly-fluidcrystal-formulation-of-setmelanotide-in-healthy-volunteers-with-obesity/"},{"d":"2020-06-23","n":"Camurus raises full year 2020 revenue guidance","u":"/media/press-releases/2020/camurus-raises-full-year-2020-revenue-guidance/"},{"d":"2020-06-15","n":"Braeburn and Camurus enter arbitration proceedings in England","u":"/media/press-releases/2020/braeburn-and-camurus-enter-arbitration-proceedings-in-england/"},{"d":"2020-06-01","n":"Camurus announces submission of request for final approval of Brixadi™ for the treatment of opioid use disorder in the US","u":"/media/press-releases/2020/camurus-announces-submission-of-request-for-final-approval-of-brixadi-for-the-treatment-of-opioid-use-disorder-in-the-us/"},{"d":"2020-05-14","n":"Camurus’ Buvidal® reimbursed in Sweden for the treatment of opioid dependence","u":"/media/press-releases/2020/camurus-buvidal-reimbursed-in-sweden-for-the-treatment-of-opioid-dependence/"},{"d":"2020-05-07","n":"Resolutions at the annual general meeting 2020 in Camurus","u":"/media/press-releases/2020/resolutions-at-the-annual-general-meeting-2020-in-camurus/"},{"d":"2020-05-07","n":"Camurus’ Interim Report January-March 2020","u":"/media/press-releases/2020/camurus-interim-report-january-march-2020/"},{"d":"2020-04-08","n":"Camurus Annual Report for 2019","u":"/media/press-releases/2020/camurus-annual-report-for-2019/"},{"d":"2020-04-06","n":"Notice of annual general meeting 2020 in Camurus AB (publ)","u":"/media/press-releases/2020/notice-of-annual-general-meeting-2020-in-camurus-ab-publ/"},{"d":"2020-04-02","n":"Camurus announces strong first quarter demand for Buvidal®","u":"/media/press-releases/2020/camurus-announces-strong-first-quarter-demand-for-buvidal/"},{"d":"2020-02-12","n":"Camurus Full year report 2019","u":"/media/press-releases/2020/camurus-full-year-report-2019/"},{"d":"2019-12-30","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2019/change-in-number-of-shares-and-votes-in-camurus/"},{"d":"2019-12-06","n":"Camurus has completed a directed share issue of approximately 3.7 million shares, raising proceeds of approximately 300 MSEK","u":"/media/press-releases/2019/camurus-has-completed-a-directed-share-issue-of-approximately-37-million-shares-raising-proceeds-of-approximately-300-msek/"},{"d":"2019-12-05","n":"Camurus intends to launch a directed share issue of up to 300 MSEK","u":"/media/press-releases/2019/camurus-intends-to-launch-a-directed-share-issue-of-up-to-300-msek/"},{"d":"2019-11-26","n":"Camurus announces new study results showing superior patient reported outcomes with Buvidal® versus standard of care in treatment of opioid dependence","u":"/media/press-releases/2019/camurus-announces-new-study-results-showing-superior-patient-reported-outcomes-with-buvidal-versus-standard-of-care-in-treatment-of-opioid-dependence/"},{"d":"2019-11-08","n":"Camurus Interim Report January-September 2019","u":"/media/press-releases/2019/camurus-interim-report-january-september-2019/"},{"d":"2019-11-08","n":"Camurus announces that FDA grants Braeburn’s Citizen Petition, eliminating the risk of further blocking of Brixadi™ from the US market","u":"/media/press-releases/2019/camurus-announces-that-fda-grants-braeburns-citizen-petition-eliminating-the-risk-of-further-blocking-of-brixadi-from-the-us-market/"},{"d":"2019-10-21","n":"Camurus to present at Jefferies 2019 London Healthcare Conference","u":"/media/press-releases/2019/camurus-to-present-at-jefferies-2019-london-healthcare-conference/"},{"d":"2019-10-15","n":"Camurus’ Nomination Committee appointed for the Annual General Meeting 2020","u":"/media/press-releases/2019/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2020/"},{"d":"2019-08-26","n":"Australian Minister for Health announced PBS listing of Buvidal® Weekly and Monthly for treatment of opioid dependence","u":"/media/press-releases/2019/australian-minister-for-health-announced-pbs-listing-of-buvidal-weekly-and-monthly-for-treatment-of-opioid-dependence/"},{"d":"2019-07-23","n":"Camurus announces positive outcome of US court proceeding about final approval of Brixadi™","u":"/media/press-releases/2019/camurus-announces-positive-outcome-of-us-court-proceeding-about-final-approval-of-brixadi/"},{"d":"2019-07-18","n":"Interim Report January-June 2019","u":"/media/press-releases/2019/interim-report-january-june-2019/"},{"d":"2019-07-16","n":"Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan","u":"/media/press-releases/2019/ra-pharmaceuticals-and-camurus-announce-exclusive-license-agreement-for-fluidcrystal-extended-release-formulation-of-zilucoplan/"},{"d":"2019-06-20","n":"Camurus receives IND acceptance from the FDA to enter Phase 3 with CAM2029 for treatment of acromegaly","u":"/media/press-releases/2019/camurus-receives-ind-acceptance-from-the-fda-to-enter-phase-3-with-cam2029-for-treatment-of-acromegaly/"},{"d":"2019-06-04","n":"Camurus announces publication of Phase 3 study results showing long-term safety, efficacy and high rates of patient satisfaction with Buvidal®","u":"/media/press-releases/2019/camurus-announces-publication-of-phase-3-study-results-showing-long-term-safety-efficacy-and-high-rates-of-patient-satisfaction-with-buvidal/"},{"d":"2019-05-09","n":"Resolutions at the annual general meeting 2019 in Camurus","u":"/media/press-releases/2019/resolutions-at-the-annual-general-meeting-2019-in-camurus/"},{"d":"2019-05-09","n":"Camurus Interim Report January-March 2019","u":"/media/press-releases/2019/camurus-interim-report-january-march-2019/"},{"d":"2019-05-07","n":"Camurus to present Interim report January-March 2019 on 9 May","u":"/media/press-releases/2019/camurus-to-present-interim-report-january-march-2019-on-9-may/"},{"d":"2019-04-15","n":"Camurus Annual Report for 2018","u":"/media/press-releases/2019/camurus-annual-report-for-2018/"},{"d":"2019-04-09","n":"Braeburn initiates court proceedings to overturn exclusivity and seeks immediate market approval of Brixadi™ in the US","u":"/media/press-releases/2019/braeburn-initiates-court-proceedings-to-overturn-exclusivity-and-seeks-immediate-market-approval-of-brixadi-in-the-us/"},{"d":"2019-04-06","n":"Positive treatment results for Buvidal® in fentanyl users presented at the ASAM 50th Annual Conference","u":"/media/press-releases/2019/positive-treatment-results-for-buvidal-in-fentanyl-users-presented-at-the-asam-50th-annual-conference/"},{"d":"2019-04-05","n":"Notice of annual general meeting 2019 in Camurus AB (publ)","u":"/media/press-releases/2019/notice-of-annual-general-meeting-2019-in-camurus-ab-publ/"},{"d":"2019-03-29","n":"Change in number of shares and votes in Camurus","u":"/media/press-releases/2019/change-in-number-of-shares-and-votes-in-camurus-2019-03-29/"},{"d":"2019-03-27","n":"Camurus’ rights issue oversubscribed","u":"/media/press-releases/2019/camurus-rights-issue-oversubscribed/"},{"d":"2019-03-26","n":"New date for publication of Camurus’ Annual Report 2018","u":"/media/press-releases/2019/new-date-for-publication-of-camurus-annual-report-2018/"},{"d":"2019-03-08","n":"Camurus publishes prospectus relating to the rights issue","u":"/media/press-releases/2019/camurus-publishes-prospectus-relating-to-the-rights-issue/"},{"d":"2019-03-05","n":"Resolutions at the Extraordinary General Meeting in Camurus","u":"/media/press-releases/2019/resolutions-at-the-extraordinary-general-meeting-in-camurus/"},{"d":"2019-02-28","n":"Camurus announces the terms of its rights issue","u":"/media/press-releases/2019/camurus-announces-the-terms-of-its-rights-issue/"},{"d":"2019-02-14","n":"Camurus to present at the Cowen and Company Annual Healthcare Conference 2019","u":"/media/press-releases/2019/camurus-to-present-at-the-cowen-and-company-annual-healthcare-conference-2019/"},{"d":"2019-02-06","n":"Full year report 2018","u":"/media/press-releases/2019/full-year-report-2018/"},{"d":"2019-02-06","n":"Notice of extraordinary general meeting in Camurus AB (publ)","u":"/media/press-releases/2019/notice-of-extraordinary-general-meeting-in-camurus-ab-publ/"},{"d":"2019-02-06","n":"Camurus to progress commercialization of Buvidal and advance pipeline programs through a fully underwritten rights issue of SEK 400 million","u":"/media/press-releases/2019/camurus-to-progress-commercialization-of-buvidal-and-advance-pipeline-programs-through-a-fully-underwritten-rights-issue-of-sek-400-million/"},{"d":"2019-02-01","n":"Camurus to present full year 2018 results on 6 February","u":"/media/press-releases/2019/camurus-to-present-full-year-2018-results-on-6-february/"},{"d":"2019-01-18","n":"Camurus to present at SEB Biotech Seminar in Stockholm","u":"/media/press-releases/2019/camurus-to-present-at-seb-biotech-seminar-in-stockholm/"},{"d":"2019-01-11","n":"Buvidal® launched as the first long-acting opioid dependence treatment in the EU","u":"/media/press-releases/2019/buvidal-launched-as-the-first-long-acting-opioid-dependence-treatment-in-the-eu/"},{"d":"2018-12-23","n":"US FDA issues a tentative approval of Brixadi™ (buprenorphine) extended-release injection for treatment of opioid use disorder","u":"/media/press-releases/2018/us-fda-issues-a-tentative-approval-of-brixadi-buprenorphine-extended-release-injection-for-treatment-of-opioid-use-disorder/"},{"d":"2018-12-11","n":"Camurus Capital Markets and R&D Day 11 December 2018","u":"/media/press-releases/2018/camurus-capital-markets-and-rd-day-11-december-2018/"},{"d":"2018-11-28","n":"Buvidal® Weekly and Buvidal® Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence","u":"/media/press-releases/2018/buvidal-weekly-and-buvidal-monthly-cam2038-approved-in-australia-as-the-first-long-acting-treatment-of-opioid-dependence/"},{"d":"2018-11-28","n":"Program for Camurus Capital Markets and R&D Day 11 December 2018","u":"/media/press-releases/2018/program-for-camurus-capital-markets-and-rd-day-11-december-2018/"},{"d":"2018-11-22","n":"Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence","u":"/media/press-releases/2018/camurus-receives-eu-approval-for-weekly-and-monthly-buvidal-cam2038-for-opioid-dependence/"},{"d":"2018-10-25","n":"Interim Report January-September 2018","u":"/media/press-releases/2018/interim-report-january-september-2018/"},{"d":"2018-10-16","n":"Camurus’ Nomination Committee appointed for the Annual General Meeting 2019","u":"/media/press-releases/2018/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2019/"},{"d":"2018-10-10","n":"Camurus to present at Jefferies 2018 London Healthcare Conference","u":"/media/press-releases/2018/camurus-to-present-at-jefferies-2018-london-healthcare-conference/"},{"d":"2018-10-09","n":"Save the date: Camurus Capital Markets and R&D Day 11 December 2018","u":"/media/press-releases/2018/save-the-date-camurus-capital-markets-and-rd-day-11-december-2018/"},{"d":"2018-09-21","n":"CHMP recommends approval of Buvidal® (CAM2038) for the treatment of opioid dependence","u":"/media/press-releases/2018/chmp-recommends-approval-of-buvidal-cam2038-for-the-treatment-of-opioid-dependence/"},{"d":"2018-09-18","n":"Camurus announces positive topline Phase 3 results for CAM2038 in opioid experienced patients with chronic low-back pain","u":"/media/press-releases/2018/camurus-announces-positive-topline-phase-3-results-for-cam2038-in-opioid-experienced-patients-with-chronic-low-back-pain/"},{"d":"2018-07-17","n":"Interim Report January-June 2018","u":"/media/press-releases/2018/interim-report-january-june-2018/"},{"d":"2018-07-16","n":"Camurus announces PDUFA date for CAM2038 for the treatment of opioid use disorder","u":"/media/press-releases/2018/camurus-announces-pdufa-date-for-cam2038-for-the-treatment-of-opioid-use-disorder/"},{"d":"2018-06-29","n":"Change in the number of shares and votes in Camurus AB","u":"/media/press-releases/2018/change-in-the-number-of-shares-and-votes-in-camurus-ab/"},{"d":"2018-06-29","n":"Camurus has completed a directed share issue of 1.1 million shares, raising proceeds of approximately SEK 102 million","u":"/media/press-releases/2018/camurus-has-completed-a-directed-share-issue-of-11-million-shares-raising-proceeds-of-approximately-sek-102-million/"},{"d":"2018-06-28","n":"Camurus updates its investor relations website","u":"/media/press-releases/2018/camurus-updates-its-investor-relations-website/"},{"d":"2018-06-28","n":"Camurus intends to launch a directed share issue of approx. MSEK 100","u":"/media/press-releases/2018/camurus-intends-to-launch-a-directed-share-issue-of-approx-msek-100/"},{"d":"2018-06-12","n":"Camurus and Medison enter into commercialization agreement for CAM2038 in Israel","u":"/media/press-releases/2018/camurus-and-medison-enter-into-commercialization-agreement-for-cam2038-in-israel/"},{"d":"2018-05-31","n":"Camurus announces positive topline results from Phase 1 study of long-acting treprostinil for the treatment of pulmonary arterial hypertension","u":"/media/press-releases/2018/camurus-announces-positive-topline-results-from-phase-1-study-of-long-acting-treprostinil-for-the-treatment-of-pulmonary-arterial-hypertension/"},{"d":"2018-05-28","n":"Camurus announces NDA resubmission of weekly and monthly buprenorphine depots to FDA","u":"/media/press-releases/2018/camurus-announces-nda-resubmission-of-weekly-and-monthly-buprenorphine-depots-to-fda/"},{"d":"2018-05-25","n":"Camurus to present at the Jefferies 2018 Global Healthcare Conference","u":"/media/press-releases/2018/camurus-to-present-at-the-jefferies-2018-global-healthcare-conference/"},{"d":"2018-05-14","n":"JAMA Internal Medicine publishes positive Phase 3 pivotal study results for Camurus’ long-acting buprenorphine depots for opioid use disorder","u":"/media/press-releases/2018/jama-internal-medicine-publishes-positive-phase-3-pivotal-study-results-for-camurus-long-acting-buprenorphine-depots-for-opioid-use-disorder/"},{"d":"2018-05-03","n":"Resolutions at the annual general meeting 2018 in Camurus","u":"/media/press-releases/2018/resolutions-at-the-annual-general-meeting-2018-in-camurus/"},{"d":"2018-05-03","n":"Interim Report January-March 2018","u":"/media/press-releases/2018/interim-report-january-march-2018/"},{"d":"2018-05-03","n":"Camurus regains worldwide development and commercialization rights to CAM2029 and related product candidates","u":"/media/press-releases/2018/camurus-regains-worldwide-development-and-commercialization-rights-to-cam2029-and-related-product-candidates/"},{"d":"2018-03-23","n":"Notice of annual general meeting 2018 in Camurus AB (publ)","u":"/media/press-releases/2018/notice-of-annual-general-meeting-2018-in-camurus-ab-publ/"},{"d":"2018-03-22","n":"Camurus Annual Report for 2017","u":"/media/press-releases/2018/camurus-annual-report-for-2017/"},{"d":"2018-03-08","n":"Camurus to present at the Cowen and Company Annual Healthcare Conference 2018","u":"/media/press-releases/2018/camurus-to-present-at-the-cowen-and-company-annual-healthcare-conference-2018/"},{"d":"2018-02-15","n":"Full year report 2017","u":"/media/press-releases/2018/full-year-report-2017/"},{"d":"2018-01-21","n":"FDA issues complete response letter for CAM2038 for opioid use disorder","u":"/media/press-releases/2018/fda-issues-complete-response-letter-for-cam2038-for-opioid-use-disorder/"},{"d":"2017-12-21","n":"First cohort dosed in Phase 1 clinical study of sustained release treprostinil injection for treatment of PAH","u":"/media/press-releases/2017/first-cohort-dosed-in-phase-1-clinical-study-of-sustained-release-treprostinil-injection-for-treatment-of-pah/"},{"d":"2017-11-07","n":"Camurus to present at Jefferies 2017 London Healthcare Conference","u":"/media/press-releases/2017/camurus-to-present-at-jefferies-2017-london-healthcare-conference/"},{"d":"2017-11-01","n":"Camurus announces that FDA advisory committee recommends approval of CAM2038 for treatment of opioid use disorder","u":"/media/press-releases/2017/camurus-announces-that-fda-advisory-committee-recommends-approval-of-cam2038-for-treatment-of-opioid-use-disorder/"},{"d":"2017-10-30","n":"Camurus announces that FDA has posted briefing material for CAM2038 Advisory Committee meeting","u":"/media/press-releases/2017/camurus-announces-that-fda-has-posted-briefing-material-for-cam2038-advisory-committee-meeting/"},{"d":"2017-10-26","n":"Interim Report January-September 2017","u":"/media/press-releases/2017/interim-report-january-september-2017/"},{"d":"2017-10-20","n":"Nomination Committee appointed in respect of AGM 2018 in Camurus","u":"/media/press-releases/2017/nomination-committee-appointed-in-respect-of-agm-2018-in-camurus/"},{"d":"2017-09-29","n":"Camurus announces European Medicines Agency validation of CAM2038 Marketing Authorization Application for treatment of opioid dependence","u":"/media/press-releases/2017/camurus-announces-european-medicines-agency-validation-of-cam2038-marketing-authorization-application-for-treatment-of-opioid-dependence/"},{"d":"2017-09-18","n":"Camurus Announces that FDA Grants Priority Review of NDA for Weekly and Monthly CAM2038 Buprenorphine Depots for Treatment of Opioid Use Disorder","u":"/media/press-releases/2017/camurus-announces-that-fda-grants-priority-review-of-nda-for-weekly-and-monthly-cam2038-buprenorphine-depots-for-treatment-of-opioid-use-disorder/"},{"d":"2017-07-20","n":"Camurus and Braeburn Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder","u":"/media/press-releases/2017/camurus-and-braeburn-announce-submission-of-nda-for-long-acting-buprenorphine-cam2038-for-opioid-use-disorder/"},{"d":"2017-07-13","n":"Interim report January-June 2017","u":"/media/press-releases/2017/interim-report-january-june-2017/"},{"d":"2017-07-12","n":"Camurus and Braeburn Pharmaceuticals Announce Topline Phase 2 Results for Long-acting Buprenorphine in Opioid Dependent Patients with Chronic Pain","u":"/media/press-releases/2017/camurus-and-braeburn-pharmaceuticals-announce-topline-phase-2-results-for-long-acting-buprenorphine-in-opioid-dependent-patients-with-chronic-pain/"},{"d":"2017-06-27","n":"Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity","u":"/media/press-releases/2017/rhythm-and-camurus-announce-positive-initial-data-for-extended-release-delivery-of-setmelanotide-for-treatment-of-rare-genetic-disorders-of-obesity/"},{"d":"2017-06-22","n":"Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder","u":"/media/press-releases/2017/long-acting-buprenorphine-blocks-opioid-effects-and-suppresses-withdrawal-symptoms-in-adults-with-opioid-use-disorder/"},{"d":"2017-06-15","n":"Camurus and Braeburn Pharmaceuticals Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine","u":"/media/press-releases/2017/camurus-and-braeburn-pharmaceuticals-announce-presentations-of-pivotal-clinical-study-data-of-long-acting-buprenorphine/"},{"d":"2017-05-03","n":"Resolutions at the annual general meeting 2017 in Camurus","u":"/media/press-releases/2017/resolutions-at-the-annual-general-meeting-2017-in-camurus/"},{"d":"2017-05-03","n":"Interim Report January-March 2017","u":"/media/press-releases/2017/interim-report-january-march-2017/"},{"d":"2017-05-02","n":"Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038","u":"/media/press-releases/2017/camurus-and-braeburn-pharmaceuticals-announce-positive-top-line-results-from-long-term-phase-3-safety-study-of-cam2038/"},{"d":"2017-03-31","n":"Camurus appoints VP Corporate Development & General Counsel","u":"/media/press-releases/2017/camurus-appoints-vp-corporate-development--general-counsel/"},{"d":"2017-03-30","n":"Camurus Annual Report for 2016 released","u":"/media/press-releases/2017/camurus-annual-report-for-2016-released/"},{"d":"2017-03-30","n":"Notice of annual general meeting 2017 in Camurus AB (publ)","u":"/media/press-releases/2017/notice-of-annual-general-meeting-2017-in-camurus-ab-publ/"},{"d":"2017-03-09","n":"Ethypharm and Camurus sign agreement for distribution of episil® in France","u":"/media/press-releases/2017/ethypharm-and-camurus-sign-agreement-for-distribution-of-episil-in-france/"},{"d":"2017-02-16","n":"Full year report 2016","u":"/media/press-releases/2017/full-year-report-2016/"},{"d":"2017-02-02","n":"Camurus to present at the Cowen and Company Annual Healthcare Conference 2017","u":"/media/press-releases/2017/camurus-to-present-at-the-cowen-and-company-annual-healthcare-conference-2017/"},{"d":"2017-01-09","n":"Camurus to present at the J.P. Morgan Annual Healthcare Conference 2017","u":"/media/press-releases/2017/camurus-to-present-at-the-jp-morgan-annual-healthcare-conference-2017/"},{"d":"2016-12-14","n":"Camurus Capital Markets and R&D Day 2016","u":"/media/press-releases/2016/camurus-capital-markets-and-rd-day-2016/"},{"d":"2016-11-25","n":"Program for Camurus’ Capital Markets and R&D Day 14 December 2016","u":"/media/press-releases/2016/program-for-camurus-capital-markets-and-rd-day-14-december-2016/"},{"d":"2016-11-14","n":"Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine for Treatment of Opioid Addiction","u":"/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-announce-positive-top-line-phase-3-results-for-long-acting-buprenorphine-for-treatment-of-opioid-addiction/"},{"d":"2016-11-11","n":"Camurus to provide an update on the progress of its research and development programs at the Jefferies 2016 Healthcare Conference","u":"/media/press-releases/2016/camurus-to-provide-an-update-on-the-progress-of-its-research-and-development-programs-at-the-jefferies-2016-healthcare-conference/"},{"d":"2016-11-08","n":"Interim report January-September 2016","u":"/media/press-releases/2016/interim-report-january-september-2016/"},{"d":"2016-11-01","n":"Camurus to host a Capital Markets Day 14 December 2016","u":"/media/press-releases/2016/camurus-to-host-a-capital-markets-day-14-december-2016/"},{"d":"2016-10-28","n":"Nomination Committee appointed in respect of AGM 2017 in Camurus","u":"/media/press-releases/2016/nomination-committee-appointed-in-respect-of-agm-2017-in-camurus/"},{"d":"2016-10-24","n":"Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to include New Combination Product for Pain and Nausea","u":"/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-expand-collaboration-and-license-agreement-to-include-new-combination-product-for-pain-and-nausea/"},{"d":"2016-10-21","n":"Braeburn Pharmaceuticals and Camurus announce the presentation of new data from clinical studies of long-acting buprenorphine","u":"/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-announce-the-presentation-of-new-data-from-clinical-studies-of-long-acting-buprenorphine/"},{"d":"2016-09-30","n":"Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for treatment of Chronic Low Back Pain","u":"/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-enroll-first-patients-in-a-phase-3-efficacy-trial-of-cam2038-for-treatment-of-chronic-low-back-pain/"},{"d":"2016-07-14","n":"Interim report January-June 2016","u":"/media/press-releases/2016/interim-report-january-june-2016/"},{"d":"2016-07-12","n":"Camurus announces completion of Phase 2 study of CAM2029 in patients with acromegaly and neuroendocrine tumors","u":"/media/press-releases/2016/camurus-announces-completion-of-phase-2-study-of-cam2029-in-patients-with-acromegaly-and-neuroendocrine-tumors/"},{"d":"2016-06-21","n":"Camurus announces results from a Phase 2 trial of CAM2032 in patients with prostate cancer","u":"/media/press-releases/2016/camurus-announces-results-from-a-phase-2-trial-of-cam2032-in-patients-with-prostate-cancer/"},{"d":"2016-06-20","n":"Richard Jameson assumes position as Camurus’ Chief Commercial Officer","u":"/media/press-releases/2016/richard-jameson-assumes-position-as-camurus-chief-commercial-officer/"},{"d":"2016-05-17","n":"Camurus Interim Report January-March 2016","u":"/media/press-releases/2016/camurus-interim-report-january-march-2016/"},{"d":"2016-05-11","n":"Braeburn Pharmaceuticals and Camurus announce positive results from Phase 2 opioid challenge study with CAM2038 in subjects with opioid use disorder","u":"/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-announce-positive-results-from-phase-2-opioid-challenge-study-with-cam2038-in-subjects-with-opioid-use-disorder/"},{"d":"2016-05-03","n":"Resolutions at the Annual General Meeting 2016 in Camurus","u":"/media/press-releases/2016/resolutions-at-the-annual-general-meeting-2016-in-camurus/"},{"d":"2016-04-21","n":"Distribution agreement signed with R-PHARM US for episil®","u":"/media/press-releases/2016/distribution-agreement-signed-with-r-pharm-us-for-episil/"},{"d":"2016-04-05","n":"Braeburn Pharmaceuticals and Camurus announce Enrollment goals reached in two pivotal Phase 3 Trials of CAM2038 for treatment of opioid dependence","u":"/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-announce-enrollment-goals-reached-in-two-pivotal-phase-3-trials-of-cam2038-for-treatment-of-opioid-dependence/"},{"d":"2016-03-30","n":"Notice of annual general meeting 2016 and proposal for new incentive program in Camurus AB (publ)","u":"/media/press-releases/2016/notice-of-annual-general-meeting-2016-and-proposal-for-new-incentive-program-in-camurus-ab-publ/"},{"d":"2016-03-30","n":"Camurus Annual Report for 2015 released","u":"/media/press-releases/2016/camurus-annual-report-for-2015-released/"},{"d":"2016-02-22","n":"Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain","u":"/media/press-releases/2016/braeburn-and-camurus-announce-initiation-of-a-phase-2-study-in-opioid-dependent-patients-with-moderate-to-severe-chronic-pain/"},{"d":"2016-02-17","n":"Full year report January-December 2015","u":"/media/press-releases/2016/full-year-report-january-december-2015/"},{"d":"2016-02-04","n":"Nomination Committee appointed in respect of AGM 2016 in Camurus","u":"/media/press-releases/2016/nomination-committee-appointed-in-respect-of-agm-2016-in-camurus/"},{"d":"2016-01-05","n":"Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide","u":"/media/press-releases/2016/rhythm-and-camurus-announce-license-agreement-for-extended-release-fluidcrystal-setmelanotide/"},{"d":"2015-12-30","n":"Braeburn Pharmaceuticals and Camurus enroll first patient in a phase 3 efficacy trial of long-acting treatment for opioid dependence","u":"/media/press-releases/2015/braeburn-pharmaceuticals-and-camurus-enroll-first-patient-in-a-phase-3-efficacy-trial-of-long-acting-treatment-for-opioid-dependence/"},{"d":"2015-12-30","n":"Change in the number of shares and votes in Camurus","u":"/media/press-releases/2015/change-in-the-number-of-shares-and-votes-in-camurus/"},{"d":"2015-12-15","n":"Braeburn Pharmaceuticals and Camurus announce start of Phase 3 trial of long-acting buprenorphine treatments for opioid dependence","u":"/media/press-releases/2015/braeburn-pharmaceuticals-and-camurus-announce-start-of-phase-3-trial-of-long-acting-buprenorphine-treatments-for-opioid-dependence/"},{"d":"2015-12-14","n":"Camurus appoints Chief Commercial Officer","u":"/media/press-releases/2015/camurus-appoints-chief-commercial-officer/"},{"d":"2015-12-10","n":"Exercise of the over-allotment option in the initial public offering of Camurus","u":"/media/press-releases/2015/exercise-of-the-over-allotment-option-in-the-initial-public-offering-of-camurus/"},{"d":"2015-12-03","n":"Final price in Camurus’s initial public offering set at SEK 57 per share – trading on Nasdaq Stockholm commences today","u":"/media/press-releases/2015/final-price-in-camuruss-initial-public-offering-set-at-sek-57-per-share--trading-on-nasdaq-stockholm-commences-today/"},{"d":"2015-11-19","n":"Camurus announces initial public offering on Nasdaq Stockholm","u":"/media/press-releases/2015/camurus-announces-initial-public-offering-on-nasdaq-stockholm/"},{"d":"2015-11-18","n":"Camurus announces initial public offering on Nasdaq Stockholm","u":"/media/press-releases/2015/camurus-announces-initial-public-offering-on-nasdaq-stockholm-2015-11-18/"},{"d":"2015-11-04","n":"FDA grants Fast Track designation for development of CAM2038, long-acting buprenorphine injections to treat opioid addiction","u":"/media/press-releases/2015/fda-grants-fast-track-designation-for-development-of-cam2038-long-acting-buprenorphine-injections-to-treat-opioid-addiction/"},{"d":"2015-10-22","n":"Camurus AB Interim Report, January - September 2015","u":"/media/press-releases/2015/camurus-ab-interim-report-january---september-2015/"},{"d":"2015-03-30","n":"Solasia acquires exclusive license and distribution rights from Camurus for episil® oral liquid in Japan and China","u":"/media/press-releases/2015/solasia-acquires-exclusive-license-and-distribution-rights-from-camurus-for-episil-oral-liquid-in-japan-and-china/"},{"d":"2014-11-20","n":"Camurus and Braeburn Pharmaceuticals sign exclusive license for long-acting buprenorphine injectables for the treatment of opioid dependence and pain","u":"/media/press-releases/2014/camurus-and-braeburn-pharmaceuticals-sign-exclusive-license-for-long-acting-buprenorphine-injectables-for-the-treatment-of-opioid-dependence-and-pain/"}]